NEW to decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC)
PROACTIVELY HELP PROTECT AGAINST MULTIPLE MYELOSUPPRESSIVE CONSEQUENCES
COSELA IS THE FIRST AND ONLY MYELOPROTECTION THERAPY
COSELA™ (trilaciclib) is administered prior to chemotherapy to help protect ES‑SCLC patients against myelosuppressive events
COSELA has been evaluated in studies based on endpoints across multiple lineages, including*:
Incidence and duration of severe neutropenia (primary endpoints)†
Incidence of Grade 3/4 anemia and red blood cell (RBC) transfusions (secondary endpoints)‡
Rate of chemotherapy dose reductions (secondary endpoint)§
Integrated safety across studies§
Evaluated in 3 randomized, double‑blind, placebo‑controlled clinical trials. The Pivotal Study (Study 1) evaluated COSELA or placebo administered prior to treatment with etoposide, carboplatin, and atezolizumab (E/P/A) in 107 patients with newly diagnosed ES‑SCLC not previously treated with chemotherapy.
Duration defined as mean days of severe neutropenia in Cycle 1.
Grade 3/4 anemia defined as Grade 3/4 decreased hemoglobin; RBC transfusions on/after 5 weeks.
Integrated safety results from Studies 1 (E/P/A), 2 (E/P), and 3 (topotecan) from patients who received at least 1 dose of COSELA (n=122) or placebo (n=118).
COSELA is indicated to decrease the incidence of chemotherapy‑induced myelosuppression in adult patients when administered prior to a platinum/etoposide‑containing regimen or topotecan‑containing regimen for extensive‑stage small cell lung cancer (ES‑SCLC).
IMPORTANT SAFETY INFORMATION
COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib.
WARNINGS AND PRECAUTIONS
Injection‑Site Reactions, Including Phlebitis and Thrombophlebitis
COSELA administration can cause injection‑site reactions, including phlebitis and thrombophlebitis, which occurred in 56 (21%) of 272 patients receiving COSELA in clinical trials, including Grade 2 (10%) and Grade 3 (0.4%) adverse reactions. Monitor patients for signs and symptoms of injection‑site reactions, including infusion‑site pain and erythema during infusion. For mild (Grade 1) to moderate (Grade 2) injection‑site reactions, flush line/cannula with at least 20 mL of sterile 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP after end of infusion. For severe (Grade 3) or life‑threatening (Grade 4) injection‑site reactions, stop infusion and permanently discontinue COSELA. Injection‑site reactions led to discontinuation of treatment in 3 (1%) of
the 272 patients.
Acute Drug Hypersensitivity Reactions
COSELA administration can cause acute drug hypersensitivity reactions, which occurred in 16 (6%) of 272 patients receiving COSELA in clinical trials, including Grade 2 reactions (2%). Monitor patients for signs and symptoms of acute drug hypersensitivity reactions. For moderate (Grade 2) acute drug hypersensitivity reactions, stop infusion and hold COSELA until the adverse reaction recovers to Grade ≤1. For severe (Grade 3) or life‑threatening (Grade 4) acute drug hypersensitivity reactions, stop infusion and permanently discontinue COSELA.
Interstitial Lung Disease/Pneumonitis
Severe, life‑threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with cyclin‑dependent kinases (CDK)4/6 inhibitors, including COSELA, with which it occurred in 1 (0.4%) of 272 patients receiving COSELA in clinical trials. Monitor patients for pulmonary symptoms of ILD/pneumonitis. For recurrent moderate (Grade 2) ILD/pneumonitis, and severe (Grade 3) or life‑threatening (Grade 4) ILD/pneumonitis, permanently discontinue COSELA.
Based on its mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should use an effective method of contraception during treatment with COSELA and for at least 3 weeks after the final dose.
Serious adverse reactions occurred in 30% of patients receiving COSELA. Serious adverse reactions reported in >3% of patients who received COSELA included respiratory failure, hemorrhage, and thrombosis.
Fatal adverse reactions were observed in 5% of patients receiving COSELA. Fatal adverse reactions for patients receiving COSELA included pneumonia (2%), respiratory failure (2%), acute respiratory failure (<1%), hemoptysis (<1%), and cerebrovascular accident (<1%).
Permanent discontinuation due to an adverse reaction occurred in 9% of patients who received COSELA. Adverse reactions leading to permanent discontinuation of any study treatment for patients receiving COSELA included pneumonia (2%), asthenia (2%), injection‑site reaction, thrombocytopenia, cerebrovascular accident, ischemic stroke, infusion‑related reaction, respiratory failure, and myositis (<1% each).
Infusion interruptions due to an adverse reaction occurred in 4.1% of patients who received COSELA.
The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.
COSELA is an inhibitor of OCT2, MATE1, and MATE‑2K. Co‑administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE‑2K substrates in the kidney (e.g., dofetilide, dalfampridine, and cisplatin).
This email was sent to email@example.com because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.